GM2 gangliosidoses

GM2 gangliosidoses
Synonyms
Pronounce	N/A
Specialty	N/A
Symptoms	Progressive neurodegeneration, muscle weakness, seizures, vision loss, hearing loss
Complications	N/A
Onset	Infancy or early childhood
Duration	Progressive
Types	Tay–Sachs disease, Sandhoff disease, AB variant
Causes	Mutations in HEXA, HEXB, or GM2A genes
Risks	Genetic predisposition, Ashkenazi Jewish heritage (for Tay–Sachs)
Diagnosis	Genetic testing, enzyme assay
Differential diagnosis	Other lysosomal storage disorders
Prevention	Genetic counseling, carrier screening
Treatment	Supportive care, enzyme replacement therapy (experimental)
Medication	N/A
Prognosis	Poor, often fatal in early childhood
Frequency	Rare
Deaths	N/A

GM2 gangliosidoses is a group of neurodegenerative diseases that are caused by the accumulation of GM2 gangliosides in the neurons. These diseases are characterized by progressive deterioration of the nervous system, leading to severe neurological impairment and early death. The GM2 gangliosidoses include Tay-Sachs disease, Sandhoff disease, and AB variant GM2 gangliosidosis.

Causes

GM2 gangliosidoses are caused by mutations in the genes that encode the enzymes responsible for the breakdown of GM2 gangliosides. These mutations result in a deficiency of these enzymes, leading to the accumulation of GM2 gangliosides in the neurons. The accumulation of these substances causes damage to the neurons, leading to the symptoms of the disease.

Symptoms

The symptoms of GM2 gangliosidoses typically begin in infancy or early childhood. They include progressive loss of mental and physical abilities, seizures, and early death. The severity and progression of the disease can vary depending on the specific mutation and the type of GM2 gangliosidosis.

Diagnosis

Diagnosis of GM2 gangliosidoses is based on the clinical symptoms, family history, and genetic testing. Genetic testing can confirm the diagnosis and identify the specific mutation causing the disease.

Treatment

There is currently no cure for GM2 gangliosidoses. Treatment is supportive and aimed at managing the symptoms of the disease. This may include medications to control seizures, physical therapy to manage muscle weakness, and nutritional support.

Prognosis

The prognosis for individuals with GM2 gangliosidoses is generally poor. Most individuals with the disease die in early childhood, although some individuals with less severe forms of the disease may live into adolescence or early adulthood.

See also

• Tay-Sachs disease
• Sandhoff disease
• Neurodegenerative diseases
• Genetic disorders

This article is a medical stub. You can help WikiMD by expanding it!
Most recent articles Ongoing trials	Wikipedia